T cell leukemia translocation alteredGenealiases: []
Q-omics provides the consensus-scored TCTA profile across patient tissues and cancer cell-line models. TCTA expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TCTA is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, TCTA RNA expression shows 18,671 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where TCTA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCTA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCTA survival associations across molecular data types. TCTA RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCTA RNA expression–survival associations across cancer types. High TCTA expression shows unfavorable associations in LGG and LAML, but favorable associations in KIRC, KIRP, LUAD and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TCTA RNA expression.
This table summarizes TCTA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TCTA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCTA shows lower tumor expression in THCA, LUAD, LUSC, KICH and KIRP and higher tumor expression in LIHC. The THCA box plot shows higher TCTA RNA expression in normal versus tumor tissue (log2 FC = −1.454, t-test p < 0.001).
This table shows molecular features associated with TCTA in patient tissues and cancer cell lines. In patient samples, TCTA shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TCTA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
